The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.
 
Juan José Soto
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Sandra Llop-Serna
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; MSD
 
Agostina Stradella
Consulting or Advisory Role - Novartis; Seagan
Travel, Accommodations, Expenses - Novartis; Novartis
 
Rafael Villanueva
Consulting or Advisory Role - Novartis
Speakers' Bureau - Lilly O.; Novartis
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Eisai; Lilly O.; Novartis; Roche
 
Mariona Calvo
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; MSD; Nerviano Medical Sciences; Roche
 
Maria Jove
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Jose Carlos Ruffinelli
Travel, Accommodations, Expenses - MSD
 
Carmen Cuadra Amor
No Relationships to Disclose
 
Ramon Salazar
No Relationships to Disclose
 
Miguel J. Gil Gil
Honoraria - Esteve; Novartis; Palex; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Seagen
 
Marta Gil-Martin
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA
Research Funding - ALX Oncology (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Juan Martin Liberal
No Relationships to Disclose